login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

First study to evaluate alternative to warfarin for mechanical heart valve patients launched


Thursday, 21 Jun 2012 11:55



The American Heart Journal has published the design of the RE-ALIGN study, the first study to evaluate dabigatran etexilate (Pradaxa, Boehringer Ingelheim) as alternative to warfarin for use in patients with mechanical heart valves requiring anticoagulation therapy.


RE-ALIGN (Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement) addresses current limitations experienced with warfarin and is designed to identify safe and effective dosing regimen of dabigatran for the prevention of valve thrombosis, stroke and systemic embolism in this patient population, prior to further investigation in a larger phase III study.The current approval of dabigatran does not cover the use in patients with mechanical heart valves.

Vitamin K antagonists, such as warfarin, are the current long-term standard for anticoagulation of patients with a cardiac valve replacement. However, there is only limited information available on the long-term risk of thrombotic and haemorrhagic complications associated with this therapy in patients with modern mechanical bileaflet valves. Additionally, in spite of frequent INR monitoring, patients treated with warfarin spend less that 65% of the time within the targeted therapeutic range (TTR), with TTR in the first three months following valve replacement surgery reported to be as low as 48.5%.


“It is vital that patients with mechanical heart valves are provided with anticoagulant therapies that are safe and effective over the long-term. The current treatment with vitamin K antagonists is associated with significant limitations, creating a need for novel options which have fewer interactions and do not require regular monitoring. We are proud to be the first company looking for an alternative option for these patients by investigating Pradaxa in the RE-ALIGN trial,” said Klaus Dugi, corporate senior vice president Medicine, Boehringer Ingelheim.


The RE-ALIGN study, a prospective, randomised, phase II study, evaluates dabigatran in patients with mechanical bileaflet heart valve during a follow-up period of 12 weeks.Based on the results, a sufficiently powered phase III study is planned to investigate efficacy outcomes for dabigatran in this patient population.


“Pradaxa has already been proven to be a safe and efficacious anticoagulant treatment for stroke prevention in patients with atrial fibrillation,” said Frans Van de Werf, Department of Cardiovascular Medicine, University Hospitals Leuven, Belgium. “However, the presence of a mechanical heart valve is a distinct clinical situation requiring different dosing. The aim of the RE-ALIGN study is to identify dosing regimens of Pradaxa that are expected to be safe and effective for the prevention of thromboembolic complications in patients with mechanical heart valves.”


The different dosing regimens that are under investigation for dabigatran in RE-ALIGN are 150mg bid, 220mg bid, and 300mg bid, with the starting dose determined by the individual patient’s creatinine clearance. The study includes patients with recent surgery for implantation of mechanical bileaflet heart valve who have not yet started oral anticoagulation, and patients who had surgery at least three months before randomisation and are currently taking an oral vitamin K antagonist. Patients are randomised to receive either dabigatran or warfarin. After the 12 week study period, patients are given the opportunity to opt-in to continue treatment with dabigatran within the RE-ALIGN extension trial, allowing investigators to collect long-term safety data.


To date, no investigation has been undertaken to determine the efficacy and safety of any novel oral anticoagulant including dabigatran in patients with mechanical heart valves. Until such data are available, the use of dabigatran for the prevention of thromboembolic complications in patients with mechanical heart valves is not recommended nor approved for clinical practice and is restricted to the setting of a randomised clinical trial only.




Add New Comment

Related Items


Most popular


Tuesday, 12 Aug 2014
Toshiba has announced that it will feature SURESubtraction Coronary at The European Society of Cardiology (ESC) congress (30 August–3 September, Barcelona, Spain). Toshiba Introduces SURESubtraction Coronary at ESC 2014

Friday, 22 Aug 2014
Royal Philips has announced that it has received 510(k) clearance from the US Food and Drug Administration to market its precision planning application for transcatheter aortic-valve implantation (TAV... FDA 510(k) clearance for TAVI precision treatment planning application

CE mark approval for Agent drug-coated balloon
Friday, 25 Jul 2014
According to Boston Scientific, the Agent drug-coated balloon provides physicians with an additional alternative to treat both in-stent restenosis and de novo small vessel coronary disease. CE mark approval for Agent drug-coated balloon

Features


Transitioning from transfemoral to transradial: Why the transradial approach is here to stay
Thursday, 21 Aug 2014
William H Crowder believes that, despite some US interventional cardiologists’ reluctance to use the approach, the transradial approach will become standard of care for coronary catheterisation ... Transitioning from transfemoral to transradial: Why the transradial approach is here to stay

The role of rotational atherectomy in contemporary PCI practice
Thursday, 07 Aug 2014
James Cockburn, David Hildick-Smith, and Adam de Belder describe their recent study (published in the International Journal of Cardiology), which found that patients who underwent rotational ... The role of rotational atherectomy in contemporary PCI practice

Profiles


David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Ashok Seth
Wednesday, 12 Feb 2014
Ashok Seth is the immediate past president of Cardiological Society of India and is the principal ... Ashok Seth

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions